Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27743787 | 0.98 | THRB (0.57) | THRBTDP1APEX1PDK2ALDH1A1 | |
| Bromomethane SCHEMBL209152 | 0.96 | THRB (0.55) | THRBTDP1APEX1PDK2ALDH1A1 | |
| Propanol SCHEMBL27824438 | 0.87 | THRB (0.47) | THRBTDP1APEX1PDK2ALDH1A1 | |
| Nonane SCHEMBL27848744 | 0.87 | TDP1 (0.47) | THRBTDP1APEX1KMT2A | |
| SCHEMBL6781995 | 0.83 | THRB (0.47) | THRBTDP1APEX1PDK2ALDH1A1 | |
| SCHEMBL4636505 | 0.82 | THRB (0.48) | THRBTDP1APEX1PDK2ALDH1A1 | |
| SCHEMBL9938667 | 0.80 | THRB (0.47) | THRBTDP1APEX1PDK2ALDH1A1 | |
| SCHEMBL30888607 | 0.80 | THRB (0.47) | THRBTDP1APEX1PDK2ALDH1A1 | |
| SCHEMBL27681372 | 0.78 | THRB (0.39) | THRBTDP1PDK2ALDH1A1MAPT | |
| SCHEMBL17275574 | 0.78 | THRB (0.46) | THRBTDP1APEX1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | ALMIRALL PRODESFARMA, SA (ES) | 2008-09-04 | — | — | US | claimed |
| EP-1725552-B1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | claimed |
| EP-1725552-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | Almirall Prodesfarma, S.A. (ES) | 2006-11-29 | — | — | EP | claimed |
| WO-2005090342-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL PRODESFARMA, SA (ES) | 2005-09-29 | — | — | WO | claimed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| WO-2005013994-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005013967-A1 | MEDICAMENTS COMPRISING PDE IV INHIBITORS AND A NOVEL ANTICHOLINERGIC AND THEIR USE FOR TREATING RESPIRATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020622-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-01-27 | — | — | US | disclosed |
| US-6815452-B2 | ANTIASTHMATIC AND ANTISPASMODIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Boehringer Ingelheim Pharma KG & Co GmbH (DE) | 2004-11-09 | — | — | US | disclosed |
| US-6790856-B2 | TROPANE 9-FLUORENE-9-CARBOXYLATE DERIVATIVES FOR TREATMENT ASTHMA, CHRONIC OBSTRACTIVE PULMONARY DISEASE, VAGALLY INDUCED SINUS BRADYCARDIA, HEART RHYTHM DISORDERS, SPASM IN URINARY OR GASTROINTESTINAL TRACTS AND MENSTRUAL PAIN | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-09-14 | — | — | US | disclosed |
| US-20040157832-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-12 | — | — | US | disclosed |
| US-20030199539-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | NQO2, QPCT, QARS1 | THRB 4152/4885TDP1 1963/4885APEX1 1347/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | THRB 1837/4885TDP1 2364/4885APEX1 2133/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | THRB 1226/4885TDP1 4836/4885APEX1 1947/4885 |
| US-20050020622-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | FPR1, AFF1, F12 | THRB 3332/4885TDP1 2753/4885APEX1 3742/4885 |
| US-20030199539-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | AFF1, FPR1, AFF4 | THRB 3645/4885TDP1 3359/4885APEX1 4192/4885 |
| US-20040157832-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | FPR1, AFF1, FPR3 | THRB 3281/4885TDP1 2599/4885APEX1 3655/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | ADRB2, CHRM3, ADRB1 | THRB 804/4885TDP1 3302/4885APEX1 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.